CIP4 is required for the hypertrophic growth of neonatal cardiac myocytes by Francesca Rusconi et al.
Rusconi et al. Journal of Biomedical Science 2013, 20:56
http://www.jbiomedsci.com/content/20/1/56RESEARCH Open AccessCIP4 is required for the hypertrophic growth
of neonatal cardiac myocytes
Francesca Rusconi, Hrishikesh Thakur, Jinliang Li* and Michael S Kapiloff*Abstract
Background: CIP4 is a scaffold protein that regulates membrane deformation and tubulation, organization of the
actin cytoskeleton, endocytosis of growth factor receptors, and vesicle trafficking. Although expressed in the heart,
CIP4 has not been studied with regards to its potential function in cardiac myocytes.
Results: We now show using RNA interference that CIP4 expression in neonatal rat ventricular myocytes is required
for the induction of non-mitotic, hypertrophic growth by the α-adrenergic agonist phenylephrine, the IL-6 cytokine
leukemia inhibitor factor, and fetal bovine serum, as assayed using morphometry, immunocytochemistry for the
hypertrophic marker atrial natriuretic factor and [3H]leucine incorporation for de novo protein synthesis. This
requirement was consistent with the induction of CIP4 expression by hypertrophic stimulation. The inhibition of
myocyte hypertrophy by CIP4 small interfering oligonucleotides (siRNA) was rescued by expression of a
recombinant CIP4 protein, but not by a mutant lacking the N-terminal FCH domain responsible for CIP4 intracellular
localization.
Conclusions: These results imply that CIP4 plays a significant role in the intracellular hypertrophic signal
transduction network that controls the growth of cardiac myocytes in heart disease.
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Myocyte hypertrophy is a compensatory response of
the heart to chronic stress whether due to volume or
pressure overload. In pathologic conditions, however,
cardiac hypertrophy is concomitant with alterations in
contractility and energy metabolism, increased cell
death, and the appearance of interstitial fibrosis that
can culminate in the development of heart failure.
These changes are controlled by a network of mitogen-
activated protein kinase, cyclic nucleotide, calcium,
and phosphoinositide-dependent intracellular signaling
pathways [1]. The identification of novel strategies by
which to attenuate pathologic remodeling remains an
important goal of cardiac signal transduction research. As
the organizers of “nodes” in the intracellular signaling
network, scaffold proteins may be of interest as potential
therapeutic targets [2].* Correspondence: jli3@med.miami.edu; mkapiloff@med.miami.edu
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reproduction in any medium, provided the orCIP4 is a modular scaffold protein involved in the
regulation of cellular morphology that can serve as an
effector for the Rho family small GTPases Cdc42, TC10,
and TCL [3]. CIP4 contains a N-terminal F-Bar (Fes-CIP4
homology [FCH] – Bin/Amphyphysin/Rvs) domain that
binds both cytoskeletal proteins and negatively-charged
membrane phospholipids, a HR1 domain that binds active,
GTP-bound Rho family members, and a C-terminal SH3
(SRC Homology 3) domain that binds a variety of proteins
involved in the regulation of the actin cytoskeleton and
small GTPase signaling (Figure 1A). As a result, CIP4 has
roles in the regulation of membrane deformation and
tubulation, dynamic remodeling of the actin cytoskeleton,
endocytosis, and vesicle trafficking [4,5]. CIP4 also
regulates filopodial and lamellipodial protrusion, affecting
the invasiveness and metastasis of cancer cells and neurite
extension in neurons [6,7]. Recently, two groups described
CIP4 knock-out mice that were normal in appearance
and fertile. One group showed that CIP4-null embryonic
fibroblasts were defective in endocytosis [4]. This was
reflected by increased GLUT4 (glucose transporter 4)
levels in skeletal muscle membranes and lower post-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CIP4 structure and expression. A. Primary structure of CIP4 showing domains and binding sites for known protein partners. “h”
indicates the 56 amino acid residue insertion present in CIP4h. B. Neonatal rat ventricular myocytes were transfected with control or CIP4 siRNA
and then stimulated with 10 μM PE, 1000 U/mL LIF, or 10% FBS for two days as indicated. CIP4 proteins in whole cell lysates were detected using
a mouse anti-CIP4 antibody. n = 4–5. † p-values vs. no drug control; * p-values vs. control siRNA-transfected myocytes treated with the same
agonist. C. Myocytes were transfected with control or CIP4 siRNA and cultured in minimal media +/− 4% horse serum for two days before TUNEL
staining. % TUNEL-positive nuclei are indicated. **p < 0.005 for CIP4 siRNA vs. control siRNA. n = 3–5.
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that despite normal development of the immune system,
the CIP4-null mice had poor T-cell function [5]. These
defects were related to impaired T cell migration and
adhesion, presumably reflecting the importance of CIP4
to regulation of the actin cytoskeleton.
Although readily detectable in the heart, nothing has
been published about the function of CIP4 and other F-Bar
proteins in the cardiac myocyte. In other cell types, CIP4
has been shown to regulate epidermal growth factor
receptor (EGFR) endocytosis [8]. Interestingly, EGFR
transactivation has been implicated in the induction of
cardiac hypertrophy by α-adrenergic, angiotensin II,
and other G-protein coupled receptors [9,10]. Cardiac
myocyte hypertrophy is non-mitotic growth of the cell
characterized by increased myofibrillar assembly and
changes in gene expression that includes a re-expression
of “fetal” genes [1]. Due to CIP4’s function in regulating
the actin cytoskeleton, we considered that CIP4 may
serve a role in the control of cardiac myocyte hyper-
trophy. We now present data that CIP4 is required for
the hypertrophic growth of cultured primary neonatal rat
ventricular myocytes in response to diverse extracellular
stimuli.Methods
Antibodies
Commercially available antibodies were as follows: mouse
anti-HA tag (Sigma), mouse anti-myc tag (monoclonal
4A6, Millipore), mouse anti CIP4 (BD Biosciences) , mouse
anti-α-actinin (monoclonal EA-53, Sigma), rabbit anti-rat
atrial natriuretic factor (ANF; US Biological), horseradish
peroxidase (HRP)-conjugated donkey secondary antibodies
(Jackson ImmunoResearch) and Alexa dye-conjugated
donkey secondary antibodies (Molecular Probes). Rabbit
anti-CIP4 antibodies OR048 and OR049 were generated
using His6-tagged CIP4 260–513 protein purified from
E. Coli DE3 RIL (Stratagene) containing pET30b-CIP4
260–513.
Expression vectors and siRNA
All CIP4 expression plasmids and adenovirus were gener-
ated using a human cDNA for the full-length 4h isoform.
pET30b-CIP4 260–513 was generated using a BamHI - SacI
fragment of the cDNA. A myc tag was added to the
N-terminus of the CIP4 open reading frame by subcloning
the CIP4 cDNA into the PspOMI – Pac I sites in the
pCMVTag3a mammalian expression vector (Stratagene).
The myc-CIP4 ΔFCH expression plasmid was generated
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wildtype vector, deleting the region encoding the first
105 amino acid residues of CIP4h. All adenovirus were
constructed by subcloning myc-tagged CIP4 cDNAs into
the pTRE shuttle vector and the Adeno-X-Tet off-system
(Clontech) and purified after amplification using Vivapure
AdenoPACK kits (Sartorius Stedim). These adenovirus con-
ditionally express recombinant proteins when co-infected
with virus expressing tetracycline transactivator (adeno-
tTA for “tet-off” or reverse tTA for “tet-on”) under the
control of the CMV promoter. All plasmid constructs
were verified by sequencing, and details of the various
constructions (including new deletion mutants gener-
ated by oligonucleotide-based site-directed mutagen-
esis) are available upon request. On-target plus siRNA
for CIP4 was CCAAAGAUGACCCCGAAAU (Dharmacon
J-095808-11-0010). Control siRNA was Dharmacon
On-Targetplus Non-targeting siRNA #1.
Neonatal rat myocytes isolation and culture
All experiments involving animals were approved by the
Institutional Animal Care and Use Committee at the
University of Miami. 1–3 day old Sprague–Dawley rats
were decapitated and the excised hearts placed in 1× ADS
Buffer (116 mM NaCl, 20 mM HEPES, 1 mM NaH2PO4,
5.5 mM glucose, 5.4 mM KCl, 0.8 mM MgSO4, pH 7.35).
The atria were carefully removed and the blood washed
away. The ventricles were minced and incubated with 15
mL 1× ADS Buffer containing 3.3 mg type II collagenase
(Worthington, 230 U/mg) and 9 mg Pancreatin (Sigma)
at 37oC while shaking at 80 RPM. After 15 minutes, the
dissociated cardiac myocytes were separated by centrifu-
gation at 50 × g for 1 minute, resuspended in 4 mL horse
serum and incubated 37oC with occasional agitation. The
steps for enzymatic digestion and isolation of myocytes
were repeated 10–12 times to maximize yield. The
myocytes were pooled and spun down again at 50 × g
for 2 minutes and resuspended in Maintenance Medium
(DMEM:M199, 4:1) supplemented with 10% horse serum
and 5% fetal bovine serum (FBS). To remove any contamin-
ating fibroblasts, the cells were pre-plated for 1 hour before
plating on gelatin-coated tissue culture plasticware. This
procedure yields >90% pure cardiac myocytes. After 1 day
in culture, the media was changed to maintenance medium
containing 0.1 mM bromodeoxyuridine (BrdU) to suppress
fibroblast growth.
Experiments were initiated 1 day after myocyte isolation.
Adenoviral infection was performed by addition of adeno-
virus (multiplicity of infection = 10–100) to the media. Plas-
mids and siRNA oligonucleotides were transfected using
Transfast (Promega) and Dharmafect 1 (Thermofisher),
respectively, as recommended by the manufacturers using
cells cultured in maintenance medium supplemented with
4% horse serum. Starting the day after gene transduction,the cells were treated for as long as 2 days, as indicated
for each experiment with 10 μM phenylephrine (PE), 10%
FBS, or 1000U/ml leukemia inhibitor factor (LIF) to
induce hypertrophy.Immunocytochemistry
Cultured neonatal cardiomyocytes on plastic coverslips
were fixed in 3.7% formaldehyde in PBS, permeabilized
with 0.3% Triton X-100 in PBS, and blocked with PBS
containing 0.2% BSA and 1% horse serum for 1 hour.
The slides were then sequentially incubated for 1 hour
with primary and Alexa fluorescent dye-conjugated
specific-secondary antibodies (Invitrogen, 1:1000) diluted
in blocking buffer. The slips were washed three times with
blocking buffer. 1 μg/mL Hoechst 33258 was included in
the last wash stop to label nuclei. Slides were sealed in
SlowFade Gold antifade buffer (Invitrogen) for fluorescent
microscopy. Wide-field images were acquired using a
Leica DMI 6000 Microscope. Myocyte immunocytochem-
istry and morphometrics was performed as previously de-
scribed by digital wide-field fluorescent microscopy using
IPLab 4.0 software (BD Biosciences) [11]. TUNEL staining
was performed using the In Situ Cell Death Detection Kit,
TMR red, (Roche) as recommended by the manufacturer.Assay for de novo protein synthesis
Myocytes were plated in 24-well, gelatin-coated tissue
culture plates at 60,000 cells per well and transfected as
above with siRNA oligonucleotides. After one day in
maintenance media with BrdU, the myocytes were incu-
bated for 24 hours in maintenance media containing
BrdU, 2 μCi [4,5-3H]leucine, and agonist as indicated.
After washing with ice-cold PBS, total proteins were
precipitated with 10% trichloroacetic acid, solubilized
with 0.4 M sodium hydroxide and analyzed by liquid
scintillation counting.Western blots
Western blots were developed using horseradish peroxid-
ase-conjugated donkey secondary antibodies, Supersignal
West Chemiluminescent Substrates (Thermo Scientific)
and a Fujifilm LAS-3000 imaging system.Statistics
All data are expressed as mean ± s.e.m. Each n repre-
sents the results of experiments using separate primary
cultures. Within each experiment, >25 cells were mea-
sured for each condition for both morphometric and
ANF expression studies. ANOVA was calculated with
α = 0.05. Post-hoc p-values were calculated using two-
tailed, paired Student's t-tests. Repeated symbols are as
follows: * p< 0.05; ** p<0.005, etc.
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As found for adult heart tissue [4], there were two CIP4
bands detectable by western blot of neonatal rat ventricular
myocyte extracts (Figure 1B). These bands represent CIP4h
and CIP4a, that are identical except for a 56 amino acid
residue insertion C-terminal to the F-Bar domain present
in CIP4h due to alternative mRNA splicing (Figure 1A)
[12]. The expression of both isoforms was consistently
induced 2–3 fold by culture of the myocytes in the presence
of hypertrophic agonists (Figure 1B), including by the α-
adrenergic agonist phenylephrine (PE), the IL-6 cytokine
leukemia inhibitory factor (LIF), and serum (FBS). We
attempted to determine the localization of CIP4 in the
cardiac myocyte by immunocytochemistry. However, the
available CIP4 antibodies did not afford a significant signal
for endogenous CIP4 protein in the myocytes, regardless
of the culture condition. We were able to express
myc-tagged CIP4h protein in the myocytes by adenoviral
infection (Figure 2). myc-CIP4 was expressed throughout
the cytosol in a reticular/punctate pattern that did not
coincide with Z-line staining by an α-actinin antibody.
The staining pattern was reminiscent of the CIP4 distri-
bution in other cell types in which CIP4 is associated
with microtubules, endosomes, membrane tubules and
other membrane structures [8,13,14].
To test whether CIP4 was required in cardiac myocytes
for hypertrophic growth, we transfected neonatal rat
ventricular myocytes with control or CIP4 specific siRNA
oligonucleotides (Figure 1B). Whether the cells were cul-
tured in minimal media or in the presence of the different
hypertrophic agonists, the expression of endogenous CIP4
protein was efficiently inhibited. As assayed by TUNEL
staining, inhibition of CIP4 expression did not induce
myocyte death when the cells were cultured in theFigure 2 CIP4 localization in myocytes. Myocytes expressing myc-CIP4 W
antibodies and Hoechst nuclear stain (blue). Bar = 20 μm. Panel A shows th
and actinin antibody staining and the nuclear stain.presence of serum (Figure 1C), albeit in the absence of
any growth stimulus, TUNEL staining was increased from
11% to 21% by the CIP4 siRNA. Likewise, CIP4 siRNA did
not induce appreciable cell death when the myocytes were
stimulated with other hypertrophic stimuli (see below).
Hypertrophic myocytes are physically larger, have
increased sarcomeric organization, express “fetal” genes
such as that for atrial natriuretic factor (ANF), and have
increased de novo protein synthesis [11,15]. Myocytes
were transfected with the CIP4 or control siRNA and
then cultured in the presence of PE, LIF, or FBS. After
two days, cross-section area was measured using morpho-
metric software and a qualitative assessment of sarcomeric
organization was performed by α-actinin staining
(Figure 3A,B). ANF expression was assayed by staining for
prepro-ANF, and [3H]leucine incorporation was used to
assay protein synthesis (Figure 3C,D). As expected, PE
and FBS induced the growth in width and length of the
control siRNA-transfected myocytes, while LIF, that
activates the gp130-LIF cytokine receptor, induced an
elongated myocyte phenotype. PE induced the most
prominent sarcomeric organization as detected by α-
actinin Z-line staining. All three stimuli induced ANF
expression strongly. Regardless of the hypertrophic
stimulus, myocytes transfected with the CIP4 siRNA were
smaller in cross-section area, while not qualitatively
different in overall proportion or sarcomeric organization
(Figure 3A,B). Importantly, the induction of ANF expres-
sion by the hypertrophic agonists was attenuated by the
CIP4 siRNA, albeit significantly only for the PE-treated
cells (Figure 3C; 45%, 35%, and 15% less for PE, LIF, and
FBS treated, CIP4 siRNA-transfected myocytes, respect-
ively). To corroborate these data, we tested by [3H]leucine
incorporation whether CIP4 siRNA could inhibit the deT were stained with myc antibodies (green) and α-actinin (red)
e green channel alone. n > 3. Panel B is a composite image of myc
Figure 3 CIP4 is important for neonatal rat ventricular myocyte hypertrophy. A. Myocytes were transfected with control or CIP4 siRNA
oligonucleotides and cultured ± 10% fetal bovine serum (FBS), 10 μM PE, or 1000 U/mL LIF. After treatment for 2 days, the myocytes were
stained for α-actinin (green), ANF (red) and Hoechst (blue); bar = 20 μm. B. Cross-section area of myocytes in A. C. Fraction of myocytes
expressing ANF in A. n = 5 for B and C. ANOVA (two-factor with replication): p-value (CIP4 siRNA vs. control siRNA) = 6 × 10-5 (B) and = 0.046
(C); p-value (between culture conditions) < 10-7 for both B and C. Post-hoc testing: * p-values vs. control siRNA-transfected myocytes treated with
the same agonist; † p-values vs. no drug control. D. [3H]leucine incorporation. n = 2. * p-value vs. PE-treated, control siRNA-transfected myocytes.
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hypertrophy. Consistent with the requirement for CIP4
expression for PE-induced ANF expression, PE-stimulated
[3H]leucine incorporation was significantly attenuated
48% by the CIP4 siRNA (Figure 3D). Taken together these
data imply that the CIP4 scaffold contributes to signal
transduction important for agonist-induced hypertrophy.
The requirement for CIP4 in hypertrophic growth was
confirmed by rescue of CIP4 expression (Figure 4A).
CIP4 siRNA or control siRNA-transfected myocytes were
infected with adenovirus expressing myc-tagged wildtype
(WT) CIP4 or the CIP4 ΔFCH N-terminal truncation
mutant that cannot properly localize to membranes or bind
microtubules [16,17]. Note that due to the PE-enhanced
activity of the CMV promoter, the adenoviral-based
expression of the wildtype and mutant CIP4 was higher inPE-treated cells, similar to endogenous CIP4. In this
experiment (Figure 4C), the PE-induced increase in
myocyte cross-section area was attenuated 42% by the
CIP4 siRNA. In addition, PE-induced ANF expression was
inhibited 63% by CIP4 siRNA (Figure 4D). Importantly,
CIP4 siRNA-transfected myocytes infected with myc-CIP4
WT adenovirus were not different in size or ANF expres-
sion than control siRNA-transfected myocytes, both in
the absence and presence of hypertrophic stimulus.
Moreover, PE-stimulated, CIP4 siRNA-transfected myocytes
expressing myc-CIP4 ΔFCH were significantly smaller and
expressed less ANF than those rescued by myc-CIP4 WT
expression, while similar in size and ANF expression to
the non-rescued CIP4 siRNA-transfected myocytes
(Figure 4B,C). Since the FCH domain confers CIP4
association with the plasma membrane and microtubules
Figure 4 The CIP4 FCH domain is important for neonatal rat ventricular myocyte hypertrophy. Neonatal rat ventricular myocytes were
transfected with control or CIP4 siRNA and then infected with adenovirus expressing myc-tagged CIP4 WT or ΔFCH protein. Myocytes were
stimulated with 10 μM PE for two days as indicated. A. CIP4 proteins were detected using a mouse anti-CIP4 antibody against human CIP4 aa
411–501. (Rat and human CIP4 are 92% identical.) B. Immunocytochemistry for α-actinin (green), ANF (red) and Hoechst (blue); bar = 20 μm.
C. Cross-section area of myocytes. n = 7. D. Fraction of myocytes expressing ANF. n = 6. ANOVA (two-factor with replication): p-value
(among the four CIP4 expression conditions) = 0.005 (C) and = 0.02 (D); p-value (± PE) < 10-6 for both B and C. Post-hoc testing: * p-values vs. CIP4
siRNA-transfected myocytes; † p-values comparing myocytes cultured ± PE; ‡ p-values vs. myc-CIP4 WT expressing myocytes.
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of the CIP4 scaffold is required to mediate hypertrophic
signal transduction in cardiac myocytes.
Conclusions
Our results demonstrate that the scaffold protein CIP4 is
required for the hypertrophic growth of neonatal cardiac
myocytes in response to diverse stimuli. Given the in-
creased CIP4 expression in neonatal myocytes cultured
in the presence of hypertrophic agonists, we expect that
CIP4 expression will be induced during the normal post-
natal maturation of the heart, if not also in cardiac
myocytes subject to pathologic stress. In other cell types,
CIP4 regulates membrane deformation and tubulation, the
cytoskeleton, endocytosis, and vesicle trafficking [4,5]. Asa result, it will be important to investigate whether in
myocytes CIP4 regulates plasmalemmal receptors or signal
transduction further downstream. The known association
of CIP4 with growth factor receptors and regulators of
the actin cytoskeleton suggests that CIP4 is important
via modulation of these pathways for the physiologic
hypertrophy present in development [8,14]. While the data
provided by PE and LIF are consistent with an additional
role for CIP4 in heart disease, experimentation using
the appropriate knock-out model is required to ascertain
whether CIP4 is required for pathological hypertrophy
in vivo. These future studies will elucidate whether CIP4
might be a therapeutic target in the prevention of heart
failure that results from pathological cardiac stress such as
in pressure overload or post-myocardial infarction.
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